Docoh
Loading...

PKI Perkinelmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.

Company profile

Ticker
PKI
Exchange
CEO
Prahlad Singh
Employees
Incorporated
Location
Fiscal year end
Former names
EG&G INC
SEC CIK
IRS number
42052042

PKI stock data

(
)

Calendar

11 May 21
4 Aug 21
29 Dec 21
Quarter (USD)
Apr 21 Jan 21 Oct 20 Jul 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jan 21 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Perkinelmer earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jul 21 Barrett Peter Common Stock Gift Dispose G No No 0 5,000 0 18,314
6 Jul 21 Gregoire Sylvie Common Stock Sell Dispose S No Yes 155.57 5,000 777.85K 17,390
6 Jul 21 Gregoire Sylvie Common Stock Option exercise Aquire M No No 46.27 5,000 231.35K 22,390
6 Jul 21 Gregoire Sylvie NQ Stock Option Common Stock Option exercise Dispose M No No 46.27 5,000 231.35K 0
10 Jun 21 Okun Andrew Common Stock Sell Dispose S No Yes 145.71 2,370 345.33K 8,252
17 May 21 Mock James M Common Stock Payment of exercise Dispose F No No 143.5 4,005 574.72K 29,324
13 May 21 Gregoire Sylvie Common Stock Sell Dispose S No No 140 5,000 700K 17,390
13 May 21 Gregoire Sylvie Common Stock Option exercise Aquire M No No 46.27 5,000 231.35K 22,390
13 May 21 Gregoire Sylvie NQ Stock Option Common Stock Option exercise Dispose M No No 46.27 5,000 231.35K 5,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

91.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 568 582 -2.4%
Opened positions 75 109 -31.2%
Closed positions 89 46 +93.5%
Increased positions 200 196 +2.0%
Reduced positions 204 188 +8.5%
13F shares
Current Prev Q Change
Total value 13.19B 14.98B -11.9%
Total shares 102.84M 104.41M -1.5%
Total puts 499.5K 140.6K +255.3%
Total calls 167.4K 201.4K -16.9%
Total put/call ratio 3.0 0.7 +327.4%
Largest owners
Shares Value Change
Vanguard 12.53M $1.61B +3.3%
Capital Research Global Investors 11.9M $1.53B -2.2%
Select Equity 9.33M $1.2B -9.7%
BLK Blackrock 7.9M $1.01B +7.6%
TROW T. Rowe Price 5.31M $681.54M +60.0%
Massachusetts Financial Services 4.41M $566.3M +6.6%
STT State Street 4.37M $560.79M -1.2%
Pictet Asset Management 2.77M $354.87M -6.2%
JHG Janus Henderson 2.51M $322.48M -22.2%
Geode Capital Management 1.97M $252.41M +0.6%
Largest transactions
Shares Bought/sold Change
TROW T. Rowe Price 5.31M +1.99M +60.0%
Select Equity 9.33M -996.83K -9.7%
Norges Bank 0 -993.66K EXIT
King Luther Capital Management 1.36M -918.57K -40.3%
Liontrust Investment Partners 0 -853.31K EXIT
FMR 610.27K -728.95K -54.4%
JHG Janus Henderson 2.51M -716.9K -22.2%
BLK Blackrock 7.9M +556.07K +7.6%
Robecosam 900.2K +433.8K +93.0%
Robeco Institutional Asset Management B.V. 967.94K +414.83K +75.0%

Financial report summary

?
Risks
  • If the markets into which we sell our products decline or do not grow as anticipated due to a decline in general economic conditions, or there are uncertainties surrounding the approval of government or industrial funding proposals, or there are unfavorable changes in government regulations, we may see an adverse effect on the results of our business operations.
  • Our growth is subject to global economic and political conditions, and operational disruptions at our facilities.
  • If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets.
  • We may not be able to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses or licensed technologies into our existing businesses, or make acquired businesses or licensed technologies profitable.
  • If we do not compete effectively, our business will be harmed.
  • Our quarterly operating results could be subject to significant fluctuation, and we may not be able to adjust our operations to effectively address changes we do not anticipate, which could increase the volatility of our stock price and potentially cause losses to our shareholders.
  • A significant disruption in third-party package delivery and import/export services, or significant increases in prices for those services, could interfere with our ability to ship products, increase our costs and lower our profitability.
  • Disruptions in the supply of raw materials, certain key components and other goods from our limited or single source suppliers could have an adverse effect on the results of our business operations, and could damage our relationships with customers.
  • If we do not retain our key personnel, our ability to execute our business strategy will be limited.
  • If we experience a significant disruption in, or breach in security of, our information technology systems or those of our customers, suppliers or other third parties, or cybercrime, resulting in inappropriate access to or inadvertent transfer of information or assets, or if we fail to implement new systems, software and technologies successfully, our business could be adversely affected.
  • We may not be successful in adequately protecting our intellectual property.
  • If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage.
  • The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability.
  • If we fail to maintain satisfactory compliance with the regulations of the United States Food and Drug Administration and other governmental agencies in the United States and abroad, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil, criminal or monetary penalties.
  • Changes in governmental regulations may reduce demand for our products or increase our expenses.
  • The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations.
  • Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability.
  • We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business.
  • Restrictions in our senior unsecured revolving credit facility and other debt instruments may limit our activities.
  • Discontinuation, reform, or replacement of LIBOR may adversely affect our variable rate debt.
  • Our share price will fluctuate.
  • Dividends on our common stock could be reduced or eliminated in the future.
Management Discussion
  • Our fiscal year ends on the Sunday nearest December 31. We report fiscal years under a 52/53 week format and as a result, certain fiscal years will contain 53 weeks. The fiscal year ending January 2, 2022 ("fiscal year 2021") will include 52 weeks, and the fiscal year ended January 3, 2021 ("fiscal year 2020") included 53 weeks.
  • Our overall revenue in the first quarter of fiscal year 2021 was $1,307.7 million and increased $655.3 million, or 100%, as compared to the first quarter of fiscal year 2020, reflecting an increase of $599.1 million, or 236%, in our Diagnostics segment revenue and an increase of $56.2 million, or 14%, in our Discovery & Analytical Solutions segment revenue. The increase in our Diagnostics segment revenue for the first quarter of fiscal year 2021 was driven by growth across our core portfolio and COVID-19 product offerings. The increase in our Discovery & Analytical Solutions segment revenue for the first quarter of fiscal year 2021 was driven by an increase in our life sciences market and applied markets revenue, as well as favorable changes in foreign exchange rates. The increase in our life sciences market revenue was the result of an increase in revenue in our pharmaceutical and biotechnology markets driven by continued growth of our Informatics business, partially offset by the loss of the extra week, rationalization of the Enterprise portfolio, and a decrease in revenue from our academia and governmental markets driven by difficult regional dynamics. The increase in our applied markets revenue was driven by increased demand from our industrial, environmental and food markets.
  • Our consolidated gross margins increased 1,283 basis points in the first quarter of fiscal year 2021, as compared to the first quarter of fiscal year 2020, primarily due to higher sales volume, favorable shift in product mix, service productivity and pricing initiatives, partially offset by increased amortization expense. Our consolidated operating margins increased 2,892 basis points in the first quarter of fiscal year 2021, as compared to the first quarter of fiscal year 2020, primarily due to higher sales volume, which was partially offset by increased costs related to amortization of acquired intangible assets, investments in new product development and growth initiatives.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Abingdon, amplified, bore, California, charge, Cooperation, decision, digital, Enterprise, Immunotec, Indian, innovation, laboratory, nontaxable, Oxford, people, permanently, repayment, retention, Rupee, storage, thereon
Removed: AB, ABO, accretion, accrue, achieved, affecting, affirmative, AFS, Aid, annuity, applying, arrangement, attempt, behalf, Beijing, beneficial, Bond, canceled, capitalizing, care, Cisbio, clarify, Code, Codification, Codolet, collected, Computing, concept, covenant, crediting, customary, deducted, deep, description, determinable, effected, eligible, employer, enacted, examination, explanation, Finland, forfeiture, Framework, France, Germany, holder, hosting, iii, implementation, inclusion, indefinitely, integration, irrevocably, jurisdiction, landscape, lengthy, leverage, lifetime, met, narrative, natural, negotiate, newly, obligation, OneSource, PBO, permission, permitted, positioned, positively, prenatal, prime, promote, proof, proportionately, prospective, ranging, rated, ratio, real, recording, refinance, refinancing, refined, reinvest, reinvestment, relevant, repatriation, repay, requirement, reset, response, Retirement, returned, salary, SAS, seasonal, Section, Shandong, shareholder, slowdown, sourcing, standard, statute, Subsequent, Subtopic, surrendered, taxing, terminate, transact, treated, undertaken, undistributed, undrawn, Yuan